To further investigate the functional role of ELOVL2 in prostate cancer (PCa), we employed siRNA-mediated knockdown to deplete ELOVL2 expression in enzalutamide-resistant LNCaP-enzR and C4-2-enzR cells. Here, ELOVL2 is linked to prostate carcinoma.